Wegovy tablets have been prescribed 3071 times in the first four days after their launch in the United States.

Analysts shared IQVIA data on Friday, showing that within the first four days of the launch of Novo Nordisk's weight-loss drug Wegovy in the United States, 3,071 prescriptions were filled. Investors are closely watching whether the company can maintain its first-mover advantage over competitors in the fiercely competitive weight-loss drug market. Barclays analysts noted in their report that these data only reflect the number of oral Wegovy prescriptions in retail channels and do not include prescriptions filled through Novo Nordisk's own NovoCare Pharmacy online channels, so the actual number of prescriptions is likely higher.